Analyst Thomas Shrader of BTIG maintained a Buy rating on Gain Therapeutics, retaining the price target of $9.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Thomas Shrader has given his Buy rating due to a combination of factors related to Gain Therapeutics’ ongoing clinical trials and the potential efficacy of their treatment. The extension of the treatment window in the P1b trial to nine months, approved by Australian regulators, enhances the likelihood of demonstrating clinical efficacy, which is a positive indicator for the company’s prospects. The trial’s focus on key biomarkers, such as alpha-Syn and Nf-L, and the inclusion of GCase-deficient patients, who may show more pronounced biomarker changes, further supports the potential success of the treatment.
Moreover, the pre-clinical evaluations have been thorough and suggest that the drug GT-02287 effectively facilitates the transport of GCase from the ER to the lysosome, where it becomes active. This mechanism is crucial for addressing Parkinson’s disease, particularly in patients with GCase mutations. The valuation of GANX, based on a discounted cash flow analysis, also supports the Buy rating, indicating a favorable financial outlook for the company.
In another report released on September 4, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.